Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

BACKGROUND: Immune checkpoint inhibition has been shown to have limited efficacy in patients with metastatic prostate cancer. Prostate cancers that harbor certain homologous recombination (HR) DNA repair gene mutations, inactivating CDK12 mutations or have underlying mismatch repair deficiency may b...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Prostate
Hlavní autoři: Markowski, Mark C., Shenderov, Eugene, Eisenberger, Mario A., Kachhap, Sushant, Pardoll, Drew M., Denmeade, Samuel R., Antonarakis, Emmanuel S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585736/
https://ncbi.nlm.nih.gov/pubmed/31972048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23955
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky